| Immune checkpoint inhibitors: recent progress and potential biomarkers P Darvin, SM Toor, V Sasidharan Nair, E Elkord Experimental & molecular medicine 50 (12), 1-11, 2018 | 1933 | 2018 |
| Immune evasion in cancer: Mechanistic basis and therapeutic strategies DS Vinay, EP Ryan, G Pawelec, WH Talib, J Stagg, E Elkord, T Lichtor, ... Seminars in cancer biology 35, S185-S198, 2015 | 1695 | 2015 |
| Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity A Jaggupilli, E Elkord Journal of Immunology Research 2012 (1), 708036, 2012 | 620 | 2012 |
| Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting B Chaudhary, E Elkord Vaccines 4 (3), 28, 2016 | 520 | 2016 |
| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 308 | 2015 |
| Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma C Ralph, E Elkord, DJ Burt, JF O'Dwyer, EB Austin, PL Stern, RE Hawkins, ... Clinical Cancer Research 16 (5), 1662-1672, 2010 | 298 | 2010 |
| Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells V Sasidharan Nair, E Elkord Immunology & Cell Biology 96 (1), 21-33, 2018 | 297 | 2018 |
| Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia S Daayana, E Elkord, U Winters, M Pawlita, R Roden, PL Stern, ... British journal of cancer 102 (7), 1129-1136, 2010 | 279 | 2010 |
| Neuropilin 1: function and therapeutic potential in cancer B Chaudhary, YS Khaled, BJ Ammori, E Elkord Cancer Immunology, Immunotherapy 63, 81-99, 2014 | 247 | 2014 |
| Myeloid‐derived suppressor cells in cancer: recent progress and prospects YS Khaled, BJ Ammori, E Elkord Immunology and cell biology 91 (8), 493-502, 2013 | 247 | 2013 |
| Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival RW Griffiths, E Elkord, DE Gilham, V Ramani, N Clarke, PL Stern, ... Cancer Immunology, Immunotherapy 56, 1743-1753, 2007 | 240 | 2007 |
| FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets R Saleh, E Elkord Cancer letters 490, 174-185, 2020 | 221 | 2020 |
| T‐cell responses and therapies against SARS‐CoV‐2 infection SM Toor, R Saleh, V Sasidharan Nair, RZ Taha, E Elkord Immunology 162 (1), 30-43, 2021 | 212 | 2021 |
| Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells E Elkord, PE Williams, H Kynaston, AW Rowbottom Immunology 114 (2), 204-212, 2005 | 212 | 2005 |
| Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression R Saleh, E Elkord Seminars in cancer biology 65, 13-27, 2020 | 205 | 2020 |
| Immune checkpoints in the tumor microenvironment SM Toor, VS Nair, J Decock, E Elkord Seminars in cancer biology 65, 1-12, 2020 | 194 | 2020 |
| Treg-mediated acquired resistance to immune checkpoint inhibitors R Saleh, E Elkord Cancer letters 457, 168-179, 2019 | 186 | 2019 |
| Single-cell transcriptome analysis highlights a role for neutrophils and inflammatory macrophages in the pathogenesis of severe COVID-19 H Shaath, R Vishnubalaji, E Elkord, NM Alajez Cells 9 (11), 2374, 2020 | 180 | 2020 |
| Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients YS Khaled, BJ Ammori, E Elkord Journal of Immunology Research 2014, 9, 2014 | 163 | 2014 |
| T regulatory cells in cancer: recent advances and therapeutic potential E Elkord, EM Alcantar-Orozco, SJ Dovedi, DQ Tran, RE Hawkins, ... Expert opinion on biological therapy 10 (11), 1573-1586, 2010 | 145 | 2010 |
Salman M ToorPostdoctoral Researcher, HBKU在 hbku.edu.qa 的电子邮件经过验证
